



EXPRESS MAIL NO.: EV452775245US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Swiercz et al.	Confirmation No.:	8301
Serial No.:	10/506,406	Art Unit:	1653
371 Filing Date:	March 14, 2005	Examiner:	To Be Assigned
Intl. Filing Date:	March 4, 2003		
For:	MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 AND METHODS BASED THEREON	Attorney Docket No:	9471-011-999
		CAM No.:	209025-999010

REQUEST FOR A CORRECTED FILING RECEIPT

Office of Initial Patent Examination's
Filing Receipt Corrections
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants respectfully request correction of the Filing Receipt for the above-captioned application. Applicants note that the Filing Receipt incorrectly identifies the title of the invention as "Modified plasminogen inhibitor type-1 and methods based thereon." The correct title of the invention is "Modified plasminogen activator inhibitor type-1 and methods based thereon," as indicated in all documents submitted by Applicants with the United States Patent and Trademark Office ("Office"). Enclosed is a copy of the Filing Receipt with the corrections noted thereon in red.

Applicants believe that no fee is due for this request since this request is necessitated by the mistake of the Office. Should any fee be required, however, please charge such fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: June 1, 2005

Margaret B. Brivanlou 40,922
Margaret B. Brivanlou (Reg. No.)

Susie S. Cheng 46,616
By: Susie S. Cheng (Reg. No.)
JONES DAY
222 East 41st Street
New York, N.Y. 10017
212-326-3939

Enclosures



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/506,406	03/14/2005	1653	914	9471-011-999	16	23	2

20583
 JONES DAY
 222 EAST 41ST ST
 NEW YORK, NY 10017



CONFIRMATION NO. 8301

FILING RECEIPT



OC000000015581012

Date Mailed: 03/30/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Rafal Swiercz, Bastrop, TX;
 Steven H. Selman, Toledo, OH;
 Jerzy Jankun, Sylvania, OH;
 Ewa Skrzypczak-Jankun, Sylvania, OH;
 Joanna Chorostowska-Wynimko, Warsaw, POLAND;

Power of Attorney: The patent practitioners associated with Customer Number 20583.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US03/06679 03/04/2003
 which claims benefit of 60/361,670 03/04/2002

Foreign Applications

Projected Publication Date: 07/07/2005

Non-Publication Request: No

Early Publication Request: No

Title

activator
Modified plasminogen inhibitor type-1 and methods based thereon

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).